美国联邦法官Ana Reyes在推翻特朗普跨性别军人禁令的诉讼中提出质疑，要求诉讼双方说明国防部长Pete Hegseth新推出的睾酮检测计划与跨性别军人激素治疗之间的差异 [1]。
法官在周三的庭审中要求双方阐明"跨性别男性与其他服役人员（包括顺性别个人）之间睾酮替代疗法的相似性和差异" [1]。此外，法官还要求五角大楼解释"在新政策和军事禁令之间对跨性别男性和其他服役人员区别对待的依据" [1]。
Hegseth近期宣布了针对服役人员的睾酮缺乏症筛查计划，规定30岁及以上军人接受年度筛查，30岁以下军人可自愿参加测试 [1]。根据新政策，睾酮替代疗法将是自愿性的 [1]。
这起诉讼由跨性别军人和寻求重新入伍的前服役人员于2025年1月底提起 [1]。该案已获得集体诉讼资格，意味着最终判决可能适用于所有服役人员 [1]。特朗普的跨性别军人禁令目前仍在实施 [1]。
U.S. District Judge Ana Reyes has challenged the Pentagon's rationale for distinguishing between testosterone replacement therapy for transgender service members and a newly announced screening program for all troops [1]. During proceedings on Wednesday in a lawsuit challenging the Trump administration's transgender military ban, the judge requested that both sides explain the medical and logistical similarities and differences between testosterone replacement therapy for transgender men and other service members [1].
The judge specifically asked the Defense Department to clarify the basis for differential treatment of transgender men and other service members under the new policy and existing military restrictions [1]. This inquiry comes as Defense Secretary Pete Hegseth has introduced an annual testosterone deficiency screening program for service members aged 30 and older [1]. Under the plan, troops under 30 may voluntarily participate in testing, while testosterone replacement therapy itself remains voluntary [1].
The lawsuit was filed in late January 2025 by transgender service members and former military personnel seeking to reenlist [1]. The case has been granted class action status, meaning any court ruling could apply to all service members [1]. The Trump administration's transgender military ban remains in effect as the litigation proceeds [1].